BioSpace News Archive

IQVIA Holdings Inc. announced that its wholly owned subsidiary, IQVIA Inc., priced an offering of €1,450,000,000 in aggregate principal amount of senior notes, consisting of €550,000,000 in aggregate principal amount of senior notes due 2026 and €900,000,000 in aggregate principal amount of senior notes due 2029.

Boston Immune Technologies today announced that they have entered into an option and license agreement aimed at developing and commercializing BITT’s innovative tumor necrosis factor (TNF) receptor 2 (TNFR2) antagonist antibodies. BeiGene has secured an option to an exclusive license to develop, manufacture, and commercialize BITT’s proprietary TNFR2 antagonist antibodies in Asia (excluding Japan), Australia, and New Zealand.

Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (“Ortho”), one of the world’s largest pure-play in vitro diagnostics companies, today announced that S&P Global upgraded Ortho’s issuer credit rating to “B” from “B-” and Moody’s investment Services (“Moody’s”) upgraded Ortho’s Corporate Family Rating to “B1” from “B3.”

Additive Orthopaedics, LLC., announced today it has received an approval order from the U.S. Food and Drug Administration (“FDA”) for its Humanitarian Device Exemption (“HDE”)

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced the pricing of its public offering of 2,439,025 shares of its common stock at a public offering price of $41.00 per share.